Journal
BLOOD
Volume 111, Issue 12, Pages 5446-5456Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2007-06-093906
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
- NCI NIH HHS [P01 CA081534, P01-CA081534] Funding Source: Medline
Ask authors/readers for more resources
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available